Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | MMP14 | P50281 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409050 | 1.00 | CA12 (0.54) | CA12CA14CA2MMP2MMP9 | |
| SCHEMBL29367675 | 1.00 | CA12 (0.54) | CA12CA14CA2MMP2MMP9 | |
| SCHEMBL42287 | 1.00 | CA12 (0.54) | CA12CA14CA2MMP2MMP9 | |
| SCHEMBL29478385 | 1.00 | CA12 (0.54) | CA12CA14CA2MMP2MMP9 | |
| SCHEMBL42286 | 1.00 | CA12 (0.54) | CA12CA14CA2MMP2MMP9 | |
| Hydrochloric Acid SCHEMBL21433626 | 0.98 | CA12 (0.53) | CA12CA14CA2MMP2MMP9 | |
| Ammonia Solution, Strong SCHEMBL466944 | 0.98 | CA12 (0.53) | CA12CA14CA2MMP2MMP9 | |
| Hydrochloric Acid SCHEMBL21433625 | 0.98 | CA12 (0.53) | CA12CA14CA2MMP2MMP9 | |
| Ammonia Solution, Strong SCHEMBL466943 | 0.98 | CA12 (0.53) | CA12CA14CA2MMP2MMP9 | |
| Hydrochloric Acid SCHEMBL6420699 | 0.98 | CA12 (0.53) | CA12CA14CA2MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 766 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459973-B2 | Peptide compounds for reducing side effects of CB1 receptor agonists | UNIVERSITAT DE BARCELONA (ES) | 2025-11-04 | — | — | US | claimed |
| EP-4358989-A2 | BICYCLIC PEPTIDYL PAN-RAS INHIBITORS | Ohio State Innovation Foundation (US) | 2024-05-01 | — | — | EP | claimed |
| EP-4041748-B1 | PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS | UNIV BARCELONA (ES) | 2024-05-01 | — | — | EP | claimed |
| CN-116554266-B | Nanometer antibacterial peptide for targeted killing of gram-positive bacteria, preparation method and application | 东北农业大学 | 2024-04-09 | — | — | CN | claimed |
| EP-4337676-A1 | ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| US-20240059737-A1 | PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS | UNIVERSITAT POMPEU FABRA (ES) | 2024-02-22 | — | — | US | claimed |
| CN-116162130-B | Enzymolysis-resistant nano antibacterial peptide and preparation method and application thereof | 东北农业大学 | 2023-10-17 | — | — | CN | claimed |
| CN-116730969-A | Beta-lapachone-amino acid conjugate, and preparation method and application thereof | 中国药科大学 | 2023-09-12 | — | — | CN | claimed |
| CN-116554266-A | Nanometer antibacterial peptide for targeted killing of gram-positive bacteria, preparation method and application | 东北农业大学 | 2023-08-08 | — | — | CN | claimed |
| CN-116162130-A | Enzymolysis-resistant nano antibacterial peptide and preparation method and application thereof | 东北农业大学 | 2023-05-26 | — | — | CN | claimed |
| EP-0417165-A1 | POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY. | EASTMAN KODAK CO (US) | 1991-03-20 | — | — | EP | claimed |
| EP-0400051-A1 | POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY. | EASTMAN KODAK CO (US) | 1990-12-05 | — | — | EP | claimed |
| EP-0156280-B1 | PROCESS FOR THE PREPARATION OF PEPTIDE INTERMEDIATES POOR IN RACEMATES, BELONGING TO GONADORELIN AND GONADORELIN ANALOGUES, THEIR SYNTHESIS AND INTERMEDIATES OBTAINED BY THIS PROCESS | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-02-07 | — | — | EP | claimed |
| WO-1989010933-A1 | POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | EASTMAN KODAK COMPANY (US) | 1989-11-16 | — | — | WO | claimed |
| WO-1989007110-A1 | POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | EASTMAN KODAK COMPANY (US) | 1989-08-10 | — | — | WO | claimed |
| US-4691008-A | COUPLING A URETHANE-BLOCKED TRIPEPTIDE AND A PEPTIDE WITH A FREE AMINE USING A CONDENSATION AGENT | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-09-01 | — | — | US | claimed |
| US-4673665-A | INDUCE OVULATION BY USING A GESTAGEN FOLLOWED BY LUTEINIZING HORMONE | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-06-16 | — | — | US | claimed |
| EP-0192742-A1 | CYCLIC POLYPEPTIDES HAVING MU-RECEPTOR SPECIFICITY | GIBSON-STEPHENS NEUROPHARMACEUTICALS, INC. (US) | 1986-09-03 | — | — | EP | claimed |
| WO-1986001516-A1 | CYCLIC POLYPEPTIDES HAVING MU-RECEPTOR SPECIFICITY | GIBSON-STEPHENS NEUROPHARMACEUTICALS, INC. (US) | 1986-03-13 | — | — | WO | claimed |
| EP-0156280-A2 | Process for the preparation of peptide intermediates poor in racemates, belonging to gonadorelin and gonadorelin analogues, their synthesis and intermediates obtained by this process | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-10-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459973-B2 | Peptide compounds for reducing side effects of CB1 receptor agonists | CNR2, CNR1, OPRD1 | CA12 2557/4885CA14 1942/4885CA2 1256/4885 |
| US-20240059737-A1 | PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS | CNR2, CNR1, OPRD1 | CA12 2650/4885CA14 1982/4885CA2 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.